Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Structural aspects of PDZ interactions
- Determination of binding motifs for PDZ domains (1)
- Determination of binding motifs for PDZ domains (2)
- Structural analysis of PSD-95 PDZ2 domain
- GluN2B interaction: the binding pocket
- GluN2B interaction: residues important for binding
- Why is valine preferred over related residues?
- GluN2B interaction: position 0 substitutions
- GluN2B interaction: –1-position substitutions
- GluN2B interaction: –2-position substitutions
- GluN2B interaction: –3-position substitutions
- Determination of binding motifs for PDZ domains (3)
- Thank you
Topics Covered
- Determination of binding motifs for PDZ domains
- Structural analysis of PSD-95 PDZ domains
- Modeling PSD-95 and GluN2B binding
- Important residues for PSD-95 and GluN2B binding
- Individual residue substitutions and binding affinities
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Hell, J. (2022, July 31). PSD-95: structural aspects of PDZ domain binding [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 22, 2024, from https://doi.org/10.69645/JVTI8232.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Johannes Hell has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
PSD-95: structural aspects of PDZ domain binding
Published on July 31, 2022
13 min
A selection of talks on Neuroscience
Transcript
Please wait while the transcript is being prepared...
0:00
As I stated in the
introduction to
Part 1 of this talk on PSD-95,
my name is Johannes Hell.
I am a Professor
of Pharmacology at
the University of
California, Davis,
Vice-Chair for
Academic Development
and the Director of our T-32
training program
in Pharmacology.
0:21
This second part will
delineate our work on
the structural details
that mediate binding of
the PDZ domains of PSD-95
to target recognition
sites on binding partners,
like the NMDAR receptor
GluN2 subunits
or the AMPAR receptor
auxiliary TARP subunits.
0:42
Starting points for
our modeling were
binding assays with
each peptide measuring
fluorescence polarization
upon addition
of increasing amounts of
individual purified PDZ domains,
which we expressed as GST
fusion proteins in E.coli.
When fluorescent molecules are
excited with polarized light,
they will maintain the
vector of the wave
when emitting fluorescence,
but tumbling will degrade the
orientation of this vector.
Small molecules tumble
faster than large ones.
When PDZ domains bind
to our peptides,
the tumbling rate will decrease
and polarization will
be better preserved.
Thus, the increase
in polarization
will reflect the binding of
PDZ domains to peptides.
We determined the K_D values
of a number of PDZ domains,
which is given as half-maximal
binding concentration
of such titration curves,
as shown here for PDZ1 and
as shown here for PDZ1
and PDZ2 from PSD-95,
and SAP102 against the peptide
visible type sequence of GluN2B.
These experiments show
that PDZ2 domains
have a significantly higher
affinity than PDZ1 domains
and that SAP102 has
a higher affinity
than PSD-95 for GluN2 subunits.